American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 12-15 , January 2009

More Is Not Always Better: Intensive Glycemic Control in Type 2 Diabetes

  • Katherine R. Tuttle, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Katherine R. Tuttle, MD, Providence Medical Research Center at Sacred Heart Medical Center, Nephrology Division, Department of Medicine, University of Washington School of Medicine, 105 W 5th Ave, Suite 350E, Spokane, WA 99224

References 

  1. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559
  2. The Action in Diabetes and Cardiovascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572
  3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471
  4. National Kidney Foundation. KDOQI (Kidney Disease Outcomes Quality Initiative) clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kid Dis. 2007;49:S1–S179
  5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986
  6. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:981–989
  7. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  8. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  9. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117
  10. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  11. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589
  12. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31(suppl 1):S12–S54
  13. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ A1c-Derived Average Glucose (ADAG) Study Group. Translating the A1c assay into estimated average glucose values. Diabetes Care. 2008;31:1473–1478

PII: S0272-6386(08)01571-0

doi: 10.1053/j.ajkd.2008.11.001

American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 12-15 , January 2009

Article Tools